STERIS plc
Analysis
STERIS is spending a record cash pile — a $600 million chemistry plant and a bigger buyback — just as its sterilization services business slows and growth guidance steps down. Whether that segment recovers in the second half decides the year.How does the fiscal 2027 growth guide compare with its medtech peers?
- The sterilization services business has quietly gone soft.
AST grew 7% for fiscal 2026 but management called it "lighter than anticipated" as customers ran down inventory. Q1 FY2027 services grew 6% and volume stayed soft — the year's guide rests on a second-half pickup that has not shown up.How much of AST's slow start was destocking versus the snowstorms?
- The company is spending its cash pile on one enormous plant.
$600 million goes into a new chemistry center in North Carolina — the largest single-site investment in its history — replacing two plants management says are not expandable. Capital spending rises to about $450 million this year.How much of the chemistry business is already at capacity today?
- Tariffs went from a cost to a small help.
They cost about $46 million in fiscal 2026; management now calls them "an okay thing for us" in fiscal 2027, with the cost flat and refunds arriving. That reversal, plus price, is what turns shrinking gross margin back into profit growth.
- Recurring revenue mixService and consumable revenue keeps growing faster than equipment, so results depend less on the timing of large capital orders and more on installed base and procedure growth.
- Pharma manufacturing reshoringPharmaceutical customers are building and localizing manufacturing capacity again, which pulls through sterilizers, washers and chemistries into new aseptic plants.
- Tariff cost stabilizationTariffs have moved from an escalating cost that limited the earnings outlook to a roughly flat expense, letting price and factory productivity reach the margin line.
- AST inventory destockingSterilization service volumes are soft because medical device customers are working down inventory, and management expects the improvement to arrive only later in the year.
- Capital shipment timingHealthcare equipment revenue swings with shipment timing and order comparisons, so quarterly growth reflects when backlog converts rather than a change in hospital demand.
- Rising capital spendingFree cash flow guidance came down as STERIS starts several large plant projects, and a higher tax rate trims what share repurchases actually add to earnings.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$1K | Jul 8 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$50K | Jun 24 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 23 | Aug 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Jun 3 | Aug 22 |
Donald Trump Republican · Executive | Purchase | ≥$15K | May 22 | Jul 1 |
Congressional trading data provided by QuiverQuant
How STERIS turned $5.9B of revenue into $1.1B of operating income.
| Revenue | ||
|---|---|---|
| Product | $3.1B | ▲ 6.56% YoY |
| Service | $2.9B | ▲ 11.12% YoY |
| Total revenue | $5.9B | |
| Gross profit | $2.6B | 44.2% |
| Operating income | $1.1B | 18.6% |